Duke Comp Cancer Ctr Core Support Grant

杜克癌症中心核心支持补助金

• 批准号: 7940213
• 负责人: HERBERT KIM LYERLY
• 金额: $ 151.8万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7940213
• 关键词: Duke; Comp; Cancer; Ctr; Core

DESCRIPTION (provided by applicant): The Duke Comprehensive Cancer Center (DCCC) is charged and empowered to serve as the center of Duke activities in cancer and to deliver the benefits of these activities to our community and society. As a matrix center continuously supported by the National Cancer Institute (NCI) for over 31 years, the DCCC leverages Duke's basic research infrastructure with clinical oncology research excellence which is enabled by treating 4,800 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and is enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. These cancer research activities are supported by $48M in NCI funding (a $27 million increase from 1998) and nearly $171 million in total research funding (a $66 million increase from 1998) and are coordinate by the DCCC and forty other center, SPORE and program project grants as well as cooperative agreements. In this competitive renewal application, we request support for 358 members (an increase of 68 since 1998) working in 11 Research Programs supported by 17 Shared Resources. Significant basic scientific advances have been made by DCCC investigators including: an understanding of DNA mismatch repair mechanisms, the role of Ras structure md signaling, and the generation of novel anti-cancer agents targeting hormone receptors. These advances are balanced with clinical and population studies such as the first clinical trial demonstrating a benefit of a new class of anti-cancer compounds, the anti-angiogenesis agents and the alpha emitter 211-Astatine; the development and demonstration of the use of umbilical cord blood as a source of stem cells for transplantation; and the development and demonstration of the use of gene expression array profiling to predict clinical outcomes in breast cancer. The DCCC has benefited from a five-year fund raising campaign which generated $113 million in philanthropic support, generated new laboratory and administrative space, enabled new Programs-in-Development in Organogenesis/Stem Cell Biology and Imaging, and enabled enhancement of Shared Resources such as Bioinformatics, Tissue and Blood Procurement, and Clinical Cellular Processing. This application for support of the DCCC articulates the principles, goals and strategies for propelling the DCCC to fully leverage the enormous advances in biomedical research to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.

描述（由申请人提供）：杜克综合癌症中心（DCCC）负责并授权作为杜克癌症活动的中心，并为我们的社区和社会提供这些活动的好处。 作为国家癌症研究所（NCI）持续支持超过31年的矩阵中心，DCCC利用杜克的基础研究基础设施和临床肿瘤学研究卓越，每年治疗4，800名新癌症患者，每年招募1，000多名患者进行治疗临床试验，并通过国家肿瘤学研究资源的存在得到加强，例如两个国家癌症研究所资助的合作团体的数据和统计中心。 这些癌症研究活动由NCI资助的4800万美元（比1998年增加了2700万美元）和近1.71亿美元的总研究资金（比1998年增加了6600万美元）支持，并由DCCC和其他40个中心，SPORE和计划项目赠款以及合作协议协调。 在这个竞争性的续约申请中，我们请求支持358名成员（自1998年以来增加了68名），他们在17个共享资源支持的11个研究项目中工作。 DCCC研究人员已经取得了重大的基础科学进展，包括：对DNA错配修复机制的理解，Ras结构和信号传导的作用，以及靶向激素受体的新型抗癌药物的产生。 这些进展与临床和人群研究相平衡，例如第一项临床试验证明了一类新型抗癌化合物、抗血管生成剂和α发射体211-Astatine的益处;开发和证明使用脐带血作为移植干细胞来源;以及开发和演示使用基因表达阵列分析来预测乳腺癌的临床结果。 DCCC受益于一项为期五年的筹款活动，该活动产生了1.13亿美元的慈善支持，产生了新的实验室和行政空间，使器官发生/干细胞生物学和成像的新项目得以发展，并使生物信息学，组织和血液采购以及临床细胞处理等共享资源得以增强。 这份支持DCCC的申请书阐明了推动DCCC充分利用生物医学研究的巨大进步的原则、目标和策略，以改善和延长患有癌症和有癌症风险的癌症患者的生命，并将其提供给社会。